Lakefront Biotherapeutics (LKFT) Change in Receivables (2016 - 2020)

Lakefront Biotherapeutics (LKFT) has 5 years of Change in Receivables data on file, last reported at $30.4 million in Q1 2020.

• Change in Receivables for Q1 2020 came in at $30.4 million, up 2262.05% year-over-year; the trailing twelve-month figure through Mar 2020 was $138.5 million (up 918.66% YoY), and the FY2025 annual result was $100.8 million, up 403.73% from the prior year.
• Change in Receivables fell to $30.4 million in Q1 2020 per LKFT's latest filing, from $105.6 million in the prior quarter.
• Over five years, Change in Receivables peaked at $105.6 million in Q4 2019 and troughed at -$19.3 million in Q2 2018.
• A 5-year average of $7.8 million and a median of -$1.4 million in 2019 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2018 and 2019: Change in Receivables plunged 287.51% in 2018, then jumped 2626.81% in 2019.
• A 5-year view of Change in Receivables shows it stood at -$5.6 million in 2016, then plunged by 144.8% to -$13.6 million in 2017, then jumped by 128.39% to $3.9 million in 2018, then jumped by 2626.81% to $105.6 million in 2019, then tumbled by 71.17% to $30.4 million in 2020.
• Business Quant data shows LKFT's Change in Receivables at $30.4 million in Q1 2020, $105.6 million in Q4 2019, and -$1.4 million in Q1 2019.